Pneumonia Clinical Trial
Official title:
IndiaCLEN Multicentric Trial of Home Versus Hospital Oral Amoxicillin for Management of Severe Pneumonia in Children
The purpose of this study is to determine the safety and efficacy of oral amoxicillin in treating WHO defined severe pneumonia(cough and fast breathing with lower chest indrawing) at home and at hospital using an open labelled multicentric prospective two-arm randomized clinical trial to determine the differences in failure of treatment with a 7 day course of oral amoxicillin administered for first 48 hours in the hospital in comparison to being sent home after enrolment, in children 3 to 59 months old who have severe pneumonia. The investigators developmental hypothesis were to test whether the community/home based oral amoxicillin is efficacious for treating severe pneumonia.
Primary objectives of this trial are to assess the rates of treatment failure (as defined
below) within the first 7 days or efficacy of a 7 day course of oral amoxycillin when
administered at home in comparison to administration of oral amoxycillin for first 48 hours
in the hospital.
Treatment failure is defined as follows-
- Clinical deterioration of disease any time after enrollment: developing any sign of
very severe disease such as persistent vomiting (vomiting repeated thrice within an
hour due to any reason), central cyanosis, grunt, stridor, abnormally sleepy or
difficult to wake, inability to drink, convulsions, or death.
- Change of antibiotic: due to persistent vomiting (vomiting of amoxycillin within 20
minutes of administration; 3 such attempts), or, developing a co-morbid condition, or
persisting fever > 98.6°F with lower chest indrawing even after 3rd day, or, fever
alone at or after day 5, or, lower chest indrawing alone (non responsive to three doses
of nebulization with bronchodilator) at or after day 5(as reported by the mother), or,
persistence of fast breathing after day 7 which is non responsive to three doses of
nebulisation with bronchodilator.
- Hospitalization: any time in home managed patients or clinical decision to extend the
hospitalization longer than 48 hours in hospitalized children or re-hospitalization in
those discharged after 48 hours from hospital. It could be related to pneumonia, or to
therapy with amoxycillin [relatedness determined by the Data & Safety Monitoring Board
(DSMB)].
- Children who need to restart antibiotics i.e. "failure of treatment", between day 8th
and day 14th due to reappearance of any danger signs, lower chest indrawing or fast
breathing which is non responsive to three trials of nebulization with bronchodilator.
- Serious adverse event considered possibly or probably related to amoxycillin.
- Left against medical advice (LAMA) or Voluntary withdrawal of consent from study from
enrollment uptill day 14th.
- Loss to follow up uptill day 14th.
Secondary objectives of this trial are to determine in children receiving oral amoxycillin
for severe pneumonia, the following:
- Determine the proportion of children who need to restart antibiotics i.e. "failure of
treatment", between day 8th and day 14th due to reappearance of any danger signs, lower
chest indrawing or fast breathing which is non responsive to three trials of
nebulization with bronchodilator.
- To identify clinical predictors at baseline and during the course of treatment that
predicts "failure of oral treatment", from enrollment till day 14th.
- The costs of home and hospital management of severe pneumonia with oral amoxycillin.
- Left against medical advice (LAMA) or Voluntary withdrawal of consent from day 7th to
day 14th.
- Loss to follow up from day 8th to day 14th.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
|
Phase 4 | |
Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT05702788 -
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 |